Company:  SYNTA PHARMACEUTICALS COR ... (SNTA)
Form Type:  10-K
Filing Date:  2/22/2012 
CIK:  0001157601 
Address:  45 HARTWELL AVE 
City, State, Zip:  LEXINGTON, Massachusetts 02421 
Telephone:  781-274-8200 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$4.15  
Change: 
-0.04 (-0.96%)  
Trade Time: 
04:00 PM EST  
Market Cap: 
$380.28M
Description of Business
Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with cancer and other severe medical conditions. Our lead drug candidate, ganetespib, is a next generation Hsp90 inhibitor in Phase 3 development for non-small cell lung cancer (NSCLC) and in a broad development program including clinical trials for breast cancer, ovarian cancer and acute myeloid leukemia (AML). In addition, we are developing a unique, proprietary platform for enhanced delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates (HDCs). All of our drug candidates were invented by Synta scientists and are fully owned by Synta. In 2013, we made significant progress in expanding the breadth of the ganetespib development program and developing our HDC platform.
Register for EDGAR Pro and access this filing in:     
  FORM 10-K
    PART I
      Item 1. BUSINESS
      Item 1A. RISK FACTORS
      Item 1B. UNRESOLVED STAFF COMMENTS
      Item 2. PROPERTIES
      Item 3. LEGAL PROCEEDINGS
      Item 4. MINE SAFETY DISCLOSURES
    PART II
      Item 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED ...
      Item 6. SELECTED FINANCIAL DATA
      Item 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL ...
        Consolidated Results of Operations
        Liquidity and Capital Resources
      Item 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT ...
      Item 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
      Item 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ...
      Item 9A. CONTROLS AND PROCEDURES
      Report of Independent Registered Public Accounting Firm
      Item 9B. OTHER INFORMATION
    PART III
      Item 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
      Item 11. EXECUTIVE COMPENSATION
      Item 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS ...
      Item 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, ...
      Item 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES
    PART IV
      Item 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
    SIGNATURES
    Report of Independent Registered Public Accounting Firm
    BALANCE SHEET
    INCOME STATEMENT
    STOCKHOLDERS EQUITY
    CASH FLOW
    Notes to Consolidated Financial Statements
  EXHIBIT 10.6.4
  EXHIBIT 23.1
  EXHIBIT 31.1
    CERTIFICATIONS UNDER SECTION 302
  EXHIBIT 31.2
    CERTIFICATIONS UNDER SECTION 302
  EXHIBIT 32.1
    CERTIFICATIONS UNDER SECTION 906
BROKERAGE PARTNERS